Brief: Getinge - Launch Of Vasoview Hemopro 3 To Occur In US During Q3 2024
March 12 (Reuters) - Getinge AB GETIb.ST :
* FDA 510(K) CLEARANCE OF VASOVIEW HEMOPRO 3, LATEST
ADDITION TO
MEDTECH COMPANY'S ENDOSCOPIC VESSEL HARVESTING (EVH) SOLUTIONS
* IS PREPARING FOR PRODUCT LAUNCH OF VASOVIEW HEMOPRO 3 TO
OCCUR
IN THE US DURING Q3 2024, WHILE REGISTRATION IN ADDITIONAL KEY
MARKETS IS UNDERWAY
Further company coverage: GETIb.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Getinge publ AB
See all newsBrief: CEO Buys SEK 4.7 Million Of Getinge Shares
Johnson & Johnson defeats heart-pump patent claims in US trial (updated)
Johnson & Johnson defeats heart-pump patent claims in US trial
Brief: Getinge's Subsidiary Maquet Cardiovascular Receives Adverse Jury Trial Verdict In Patent Infringement Dispute With Abiomed In U.S.
Getinge lags profit estimates as uncertainty curbs investments in medical equipment